Leukemia research · 2020
Sweet's syndrome associated with hematological malignancies.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Maller Bradley, Bigness Alec, Moiño Daniela, Greene John
Аннотация
BACKGROUND: Sweet's syndrome, or acute febrile neutrophilic dermatosis, is often mistaken for a skin infection given its similar clinical presentation.
OBJECTIVE: To describe the clinical presentations and management of a rare dermatologic condition associated with hematological malignancies.
METHODS: Case series; Chart review of patients at Moffitt Cancer Center between 2017 and 2020.
RESULTS: The subjects are a 79 year-old man (Patient 1) with Myelodysplastic Syndrome (MDS), a 66 year-old woman (Patient 2) with Acute Myeloid Leukemia (AML), a 56 year-old man (Patient 3) with AML, and a 69 year-old man (Patient 4) with MDS. Patient 1 was initially misdiagnosed with neutropenic fever. Patient 2 was incidentally discovered to have erythematous skin lesions prior to initiating chemotherapy. Before starting second line chemotherapy, patient 3 developed pathergy at the site of a PICC line. Patient 4 developed erythema around a newly placed port before initiating chemotherapy. Only patients 1 and 3 received glucocorticoids. Patients 2, 3, and 4 were able to initiate chemotherapy without further complications.
LIMITATIONS: Heterogeneity of subjects in terms of prognostic factors, stage at diagnosis, and treatment strategies.
CONCLUSION: Early recognition and treatment of malignancy-associated Sweet's syndrome is imperative to limit patient morbidity and expeditiously provide anti-cancer treatments.
OBJECTIVE: To describe the clinical presentations and management of a rare dermatologic condition associated with hematological malignancies.
METHODS: Case series; Chart review of patients at Moffitt Cancer Center between 2017 and 2020.
RESULTS: The subjects are a 79 year-old man (Patient 1) with Myelodysplastic Syndrome (MDS), a 66 year-old woman (Patient 2) with Acute Myeloid Leukemia (AML), a 56 year-old man (Patient 3) with AML, and a 69 year-old man (Patient 4) with MDS. Patient 1 was initially misdiagnosed with neutropenic fever. Patient 2 was incidentally discovered to have erythematous skin lesions prior to initiating chemotherapy. Before starting second line chemotherapy, patient 3 developed pathergy at the site of a PICC line. Patient 4 developed erythema around a newly placed port before initiating chemotherapy. Only patients 1 and 3 received glucocorticoids. Patients 2, 3, and 4 were able to initiate chemotherapy without further complications.
LIMITATIONS: Heterogeneity of subjects in terms of prognostic factors, stage at diagnosis, and treatment strategies.
CONCLUSION: Early recognition and treatment of malignancy-associated Sweet's syndrome is imperative to limit patient morbidity and expeditiously provide anti-cancer treatments.
Предметные рубрики MeSH
AgedAnti-Inflammatory AgentsAntineoplastic Combined Chemotherapy ProtocolsBiopsyDelayed DiagnosisDiagnostic ErrorsFatal OutcomeFebrile NeutropeniaFemaleGlucocorticoidsHumansLeukemia, Myeloid, AcuteLeukemia, Myelomonocytic, AcuteLymphoma, B-Cell, Marginal ZoneMaleMiddle AgedMyelodysplastic SyndromesPyoderma GangrenosumRespiratory Tract InfectionsSkinSweet Syndrome